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Abstract 
Background: Rubella virus infection during pregnancy is associated with adverse fetal outcomes and reproductive 
failures. In Ethiopia, little is known about the extent of the disease and rubella vaccination is not widely available. 
The main aim of this study was to assess the sero-prevalence of the rubella virus infection and its associated risk 
factors among pregnant women. 
Methods: An institution based cross-sectional study was conducted in the antenatal clinics of Debre Markos and 
Debre Tabor hospitals of Amhara Region, Northwest Ethiopia from March to June2015. Study participants were 
recruited until the calculated sample size was achieved at both hospitals. Data on socio-demographic and factors 
associated with rubella virus infection were collected through a structured questionnaire. A 5ml blood sample was 
also collected from all study participants and tested for Immunoglobulin (Ig) G and IgM antibodies against rubella 
virus infection using enzyme immune assay (EIA) test at the Amhara Regional Health Research Laboratory Center, 
Bahir Dar. Data were analyzed using SPSS version 21 and frequencies, chi-square tests and Odds ratio were 
computed using a p value < 0.05 as a level of significance.  
Result: A total of 401 pregnant mothers were screened for rubella virus infection. The mean age of the study 
participants was 26.4 year (SD= 5.4) and the overall sero-prevalence of rubella anti-IgG was 46.4%. In connection, 
the sero-prevalence of anti-IgM among anti-IgG sero-positive cases was 3.2%. Pregnant women at first trimester 
(OR=2.49, 95% CI= 1.14-5.42) and HIV sero-status (OR= 0.33, 95% CI= 0.15-0.76) were factors found to be 
significantly associated with rubella anti-IgG sero-prevalence (p<0.05).  
Conclusion: The sero-prevalence of rubella virus infection among pregnant women was considered to be low, 
showing the high risk of a new infection. In addition to a comprehensive surveillance approach and efforts to 
determine rubella susceptibility profile among school-aged girls and women of childbearing age, it is also important 
to consider rubella vaccine in a national vaccination program.  [Ethiop. J. Health Dev.  2018;32(3):00-000] 
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Background 
Rubella (also called German measles or three-day fever) 
is among the TORCH infections, which also include 
Toxoplasmosis, Other (syphilis, varicella-zoster, 
parvovirus B19), Cytomegalovirus (CMV), and Herpes 
infections (1-4). These infections are commonly 
characterized by their easily transmissible nature from 
mother to fetus during pregnancy and are also 
responsible for congenital anomalies and possibly 
stillbirths (3-5). The rubella virus is an enveloped, single 
stranded, positive sense RNA virus belonging to the 
Togaviridae family (6). The viral genome encodes for 
five proteins, three structural proteins (two 
glycoproteins, E1 and E2 and the capsid protein) and 
two non-structural proteins (p90 and p150). The E1 
glycoprotein contains the antigenic determinants that 
induce major immune responses and a hemagglutination 
inhibiting and hemagglutination-neutralizing epitope (7, 
8). 
 
Rubella is a contagious disease usually manifested by a 
mild fever and rash, mostly in young adults and children. 
However, it can cause a serious birth defect called 
congenital rubella syndrome (CRS) when a pregnant 
woman becomes infected, particularly during the first 
trimester (9-11). The birth defects associated with CRS 
are ophthalmic, auditory, cardiac, and craniofacial. 
Infants with CRS who survive the neonatal period may 
face serious developmental disabilities and have an 
increased risk for developmental delay, including 
autism (5,9,10). Based on a 2015 World Health 
Organization (WHO) update, globally, over 100,000 
babies are born with CRS every year (11). The rate of 
congenital defects and spontaneous abortion due to 
rubella virus infection among fetuses can be estimated 
to 65–85 % when acquired during the first two months 
of gestation (8). Despite these potentially devastating 
consequences, many developing countries, including 
Ethiopia, are yet to include control and prevention of 
rubella virus infection within their national health 
strategies (12). 
 
Both humoral and cell-mediated immunity develop 
following rubella virus infection. Although natural 
rubella infection generally confers lifelong immunity, 
rare cases of serologically confirmed re-infections after 
earlier infection (or immunization) have been reported 
(13). Immunoglobulin (Ig) G and IgM antibodies are 
observed about 14-18 days after rubella infection, at 
about the time when the rash appears. Rubella IgM 
antibodies wane quickly and are usually undetectable 
after two months, whereas rubella IgG antibodies persist 
(14). Serologic tests such as enzyme immunoassay 
(EIA) that have been calibrated against the WHO 
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international standard (RUB-1-94) are important tools to 
measure rubella specific IgG and IgM, and are 
considered convenient, sensitive, and accurate methods 
of screening for rubella virus infection (13,15). 
Currently, there is no specific treatment for rubella virus 
infection. However, the rubella virus infection can be 
prevented by vaccination which can be available either 
in monovalent formulation or more commonly in 
combinations with other vaccines such as with vaccines 
against measles (MR), measles and mumps (MMR), or 
measles, mumps and varicella (MMRV). Large-scale 
rubella vaccination campaigns in the last decade have 
significantly reduced rubella and associated CRS in 
many developed nations (11). 
 
In developed countries, the diagnosis of rubella virus is 
part of prenatal health assessment and also used for 
understanding the prevalence of the infection, which 
varies widely in different countries. In sub-Saharan 
Africa, the sero-positivity of prevalence of rubella virus 
ranges from 66% to 99% (16). Due to socioeconomic 
and other factors, pregnant women in developing 
countries including Ethiopia generally do not undergo 
routine antibody screening for rubella virus infection 
(4,17). Although little is known about rubella 
epidemiology and the incidence of CRS in Africa, it has 
been estimated that 110,000 CRS cases occur each year 
during non-epidemic years in developing countries (15). 
 
 In Ethiopia, despite measles case-based surveillance 
system, there is lack of a national screening program for 
rubella virus infection. Reports showed that rubella is 
endemic in Ethiopia (12, 18-20). However, there is no 
documented data regarding the prevalence of rubella 
virus infection during pregnancy. Furthermore, rubella 
vaccine is not included in the Ethiopian national 
immunization programme. Thus, the aim of this study 
was to assess the sero-prevalence of the rubella virus 
infection and its associated risk factors among pregnant 
women who attend antenatal care (ANC) in two 
hospitals of Amhara Region, Northwest Ethiopia. 
 
Methods 
Study setting:  This hospital based study was conducted 
at the antenatal clinics of Debre Markos and Debre 
Tabor hospitals of Amhara region, Northwest Ethiopia. 
Debre Markos hospital is the main public hospital in 
East Gojjam situated in Debre Markos city, the capital 
of East Gojjam zone. Similarly, Debre Tabor hospital is 
the main public hospital in the South Gonder zone 
situated in Debre Tabor city. Both are district hospitals 
providing different services including antenatal care for 
pregnant women. 
 
Study design and period:  A hospital based cross-
sectional study design was employed from March to 
June 2015. 
 
Study participants:  Study participant were recruited 
from pregnant women who were seeking services at the 
antenatal clinics of the two hospitals during the study 
period and who volunteered to participate in the study.  
Participants were recruited sequentially until the 
maximum sample size was achieved. A total of 401 
pregnant women - 200 from Debre Markos Hospital and 
201 from Debre Tabor Hospital - were included in the 
study based on the following assumption; 50% 
prevalence, 5% marginal error, 95% confidence interval 
and 10% non-response rate. The calculated sample size 
was equally divided between the hospitals as they 
represent the wide range of two major districts of the 
Northwest Ethiopia. 
  
Data collection and laboratory procedures:  Interviews 
were conducted using structured questionnaires to 
collect information on the socio-demographic 
characteristics and associated risk factors. Nurses were 
specifically trained on how to collect the data. About 
5ml venous blood sample was collected from all study 
participants by medical laboratory professionals. Blood 
samples were centrifuged and serum was separated and 
stored at -200C until centrally processed at Bahir Dar 
Regional Health Research Laboratory Center 
(BRHRLC) using Enzyme Immuno Assay (EIA) 
technique (rubella IgG and IgM EIA test kit, Linear 
Chemicals, Barcelona) according to the manufacturer’s 
instructions. 
 
Rubella sero-positivity was diagnosed by both rubella 
IgG and IgM Enzyme Immunoassay (EIA) test kits. The 
Kits are a solid phase enzyme immunoassay based on 
indirect principle for the qualitative and quantitative 
detection of IgG and IgM antibodies to rubella in human 
serum. The microwell plate is coated with rubella 
antigens. If the specimens contain IgG or IgM antibodies 
to rubella, they will bind to the antigens coated on the 
microwell plate to form immobilized antigen-rubella 
IgG or IgM antibody complexes. Consequently, 
substrate A and B are added to produce a color that is 
measured at 4540nm with a microplate reader. The 
sensitivity and specificity of rubella IgG EIA test kit is 
96.4% and >99.0% respectively. Similarly, the 
sensitivity and specificity of rubella IgM test kit is 
90.0% and 94.9% respectively. 
 
Data analysis:  Data entry was conducted using Epi 
Data 3.1 and analysis was performed using SPSS, 
Version 21 (IBM-SPSS Inc) software. The socio-
demographic characteristics of the study participants 
were summarized by proportions and categorical data 
were compared by Pearson’s Chi-square. Binary and 
multivariable logistic regression analyses were used to 
assess factors associated with the rubella virus infection 
and at95% confidence interval. Statistical significance 
was set to P-value < 0.05. 
 
Results 
The mean age of study participants was 26.4 (SD= 5.4), 
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Table 1: Socio-demographic characteristics of pregnant women from Debre Markos and Debre Tabor 
hospitals of Northwest Ethiopia, 2015.  





Age in years  < 20 52 (13.0) 28 (53.8) 24 (46.2) 0.350 
21-30  281 (70.1) 124 (44.1) 157 (55.9)  
>31 68 (16.9) 34 (50.0) 34 (50.0)  
Residence  Urban  300 (74.8) 134 (44.7) 166 (55.3) 0.235 
Rural  101 (25.2) 52 (51.5) 49 (48.5)   
Marital status  Married  397 (99.0) 183 (46.1) 214 (53.9) 0.249 





81 (20.3) 35 (43.2) 46 (56.8) 0.529 
Primary 
school 
80 (20.0) 42 (52.5) 38 (47.5)  
High school  103 (25.8) 50 (48.5) 53 (51.5)  
College or 
university  
136 (34.0) 59 (43.4) 77 (56.6)  
Occupational 
status  
Employee  96 (23.9) 35 (36.5) 61 (63.5) 0.083 
House wife  168 (41.9) 80 (47.6) 88 (52.4)  
Merchant  60 (15.0) 28 (46.7) 32 (53.3)  
No job 77 (19.2) 43 (55.8) 34 (44.2)  
Monthly income  <1000 128 (34.1) 59 (46.1) 69 (53.9) 0.700 
1001-3000 154 (41.1) 74 (48.1) 80 (51.9)  
3001-5000 66 (17.6) 26 (39.4) 40 (60.6)  
>5001 27 (7.2) 12 (44.4) 15 (55.6)  
# P value of Chi-square test 
 
Based on EIA for rubella virus the overall sero-prevalence of rubella anti-IgG was 46.4% and the sero-prevalence 
of anti-IgM within IgG sero-positive was 3.2%. Although it was not statistically significant, the IgG sero-prevalence 
of rubella virus was relatively higher among pregnant women from Debre Tabor hospital (Table 2). 
  
 
Table 2: Sero-prevalence of rubella virus among pregnant women from Debre Markos and Debre Tabor 
hospitals of North West Ethiopia.  
 
Character  













Anti-Rubella IgG 186 (46.4) 215 (53.6) 87 (43.5) 113 (56.5) 99 (49.3) 102 (50.7) 
Anti-Rubella IgM* 6 (3.2) 179 (96.8) 3 (3.4) 84 (96.6) 3 (3.0) 96 (97.0) 
*Within Rubella IgG positive, IgG= immunoglobuline G, IgM= immunoglobuline M 
 
 
In Table 3 below, the bivariate logistic regression 
analysis shows that stage of pregnancy (OR=2.49, 95% 
CI= 1.14-5.42) and HIV-sero status (OR= 0.33, 95% 
CI= 0.15-0.76) were significantly associated with 
rubella virus sero-positivity. Pregnant women who were 
on their first trimester were about three times more 
likely to be positive for anti-rubella IgG compared to 
those women in their third trimester (AOR= 3.16, 95% 
CI= 1.36-7.36). Similarly, those pregnant women with 
HIV infection were found to be about five times 
(AOR=5.14, 95% CI= 1.94-13.57) more likely to be 
positive for rubella virus infection (Table 3). However, 
the association between rubella virus sero-positivity and 
other factors like gravidity, source of drinking water, 
history of spontaneous abortion, history of neonatal 
death, history of premature delivery, alcohol 
consumption, and history of reproductive tract infection 
and history of other chronic diseases other than 
HIV/AIDS were found to be statistically insignificant 
(p>0.05).
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Crude Odds Ratio 
(95% CI) 




Time of pregnancy 1st trimester 32(8.3) 21(11.9) 2.49[1.14-5.42] 0.022 3.16[1.36-7.36] 0.027 
2nd trimester 140(36.5) 64(36.2) 1.09[0.71-1.68] 0.668 1.23[0.77-1.94]  
3rd trimester 212(55.2) 92(52.0) 1  1  
Gravidity Prim-gravidae 164(41.2) 80(43.5) 1 0.393 - - 
Multi-gravidae 234(58.3) 104(56.5) 0.84[0.56-1.25]  - - 
Source of drinking water Pipe 316(79.0) 148(80.0) 1 0.649 - - 
Other sources* 84(21.1) 37(19.0) 0.89[0.55-1.45]  - - 
HIV sero-status Negative 349(87.5) 167(90.3) 1 0.009 1 0.001 
Positive 16(4.0) 10(5.4) 1.82[0.65-5.11]  5.14[1.94-13.57]  
Not known 34(8.5) 8(4.3) 0.33[0.15-0.76]  - - 
History of spontaneous 
abortion 
No 347(86.5) 158(85.9) 1 0.387 - - 
Yes 54(13.5) 28(15.1) 1.29[0.73-2.28]  - - 
History of neonatal death No 368(92.0) 170(91.9) 1 0.941 - - 
Yes 32(8.0) 15(8.1) 1.03[0.49-2.12]  - - 
History of premature 
delivery 
No 385(96.7) 178(96.7) 1 0.995 - - 
Yes 13(3.3) 6(3.3) 0.99[0.33-3.02]  - - 
Alcohol consumption  No  298(74.3) 137(73.7) 1 0.779 - - 
Yes  103(25.7) 49(26.3) 1.06[0.68-1.67]  - - 
History of other chronic 
diseases** 
No  392(97.8) 183(98.4) 1 0.433 - - 
Yes  9(2.2) 3(1.6) 0.57[0.14-2.32]    
*Includes: spring and river ** Includes chronic diseases other than HIV/AIDS 
Rubella virus sero-prevalence and associated factors among non-vaccinated pregnant women     5 
 
Ethiop. J. Health Dev.  2018;32(3) 
 
Discussion  
Due to the absence of vaccination programs CRS is more 
common in developing countries compared to developed 
nations. The incidence of rubella virus among the 17-22 
age group was estimated to be 80-88% in less developing 
part of the world. Consequently, 12-20% of these 
populations are still susceptible to infection with the 
rubella virus (21).  
This study assessed the sero-prevalence of rubella virus 
and its associated risk factors among pregnant women in 
Northwest Ethiopia. The results showed that the sero-
prevalence of anti-rubella virus IgG was 46.4%. This is 
significantly lower than the previous study conducted in 
Ethiopia among young adult females (88% to 94%) (19) 
in major cities of the country. The sero-prevalence of 
rubella virus appears to vary among different communities 
by geographic locations based on their vaccination status 
and occurrences of epidemic. Similar studies from other 
non-vaccinated African countries reported higher IgG 
sero-prevalence among pregnant women, for example in 
Benin (94.0%) (23), in Burkina Faso (77.0%, 95.0%) 
(17,24), in Egypt (87.3%) (22) and in Sudan (95.1%) (25) 
which were notably higher prevalence compared to the 
findings in this study. 
 
Though there is substantial transmission of rubella virus in 
the study area, our results show that the majority of the 
study participants (53.6%) were not immune against 
rubella virus. The lower sero-prevalence of anti-rubella 
IgG in this study might be linked with the absence of 
rubella vaccination in the national vaccination campaign. 
As there is no surveillance programme of rubella virus 
infection and CRS in the country, it is important to 
determine the risk and level of CRS to determine the need 
for introduction of rubella vaccination especially during 
early in life. 
 
Though it is not statistically significant, our study reported 
that there was an increased proportion of anti-rubella IgG 
sero-positivity as the age of pregnant mothers’ increases. 
This finding is found to be consistent with the study 
reported from Nigeria and Burkina Faso (17,26). The 
relationship between HIV and rubella virus is poorly 
understood. In our study HIV sero-status was found to be 
significantly associated with rubella sero-positivity. Thus, 
further study with strong statistical power and longitudinal 
design is recommended to understand the relationship 
between these two infections. 
 
A potential limitation of this study is the temporal 
relationship that may be interpreted because of its cross-
sectional design. The use of nurses in the ANC as data 
collectors may have also introduced desirability bias. The 
absence of association between various risk factors and 
rubella virus might be because the study did not have 
strong statistical power to detect the differences. This 
study overlooked the importance of including clinical 
data, outcome of the pregnancy and the sero-positivity of 
the newly born babies which would have been a good 
opportunity to describe the clinical presentation and the 
consequences of rubella virus infection during pregnancy 
on the newborn. 
 
Conclusion and Recommendation: 
In this study, the rubella virus sero-prevalence was found 
to be low as compared to other similar studies. On the 
contrary, susceptibility to rubella virus infection is 
believed to be very high in the study areas the pregnant 
women were all unvaccinated. In order to better 
understand the burden and epidemiology of rubella and 
CRS, the Ethiopian Ministry of Health may consider 
adopting a comprehensive approach to surveillance, 
establishing sentinel surveillance for CRS, and conducting 
appropriate studies to assist in defining the rubella 
susceptibility profile in school-aged girls and women of 
childbearing age. Information from such studies will be 
useful in the consideration of appropriate rubella control 
strategies in Ethiopia. 
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